- Hong Kong led global IPO fundraising in 2025 with HK$285.8bn from 119 listings, up 68% in deal count and more than 2x in proceeds versus 2024.
- Proceeds were concentrated in a handful of mega-IPOs, with industrials & materials leading capital raised while consumer, IT/telco and healthcare drove listing volume.
- PwC expects ~150 IPOs in 2026 raising HK$320–350bn, with more HK$5bn+ deals and continued momentum from new-economy and A-share (A+H) issuers.
- Key risks are geopolitics, rates and evolving tech/AI regulation, while HKEX reforms (e.g., specialist tech and biotech regimes) support the pipeline.
Read More
The PwC report and corroborating analyses show that 2025 has proven to be a breakout year for the Hong Kong IPO market. With nearly HK$285.8 billion raised over 119 IPOs, Hong Kong reclaimed the global top position for IPO fundraising—driven by large “mega-IPOs,” sectoral shifts toward industrials, materials and technology, and growing international/investor confidence.
From an investor banking perspective, several strategic dynamics are emerging. First, listings by A-share companies (so-called A-H listings) have played an outsized role in funds raised—and this is likely to continue as mainland Chinese firms increasingly view Hong Kong as a gateway to international capital. Similarly, the introduction of specialist technology listing regimes (18C innovation, 18A biotech) and the TECH enterprise channel have lowered regulatory frictions for early-stage and innovative companies.
Second, there has been a divergence between the number of listings and where capital is concentrated: while 119 listings reflect strong deal flow, a small number of large IPOs (55 raising HK$1 billion+, several exceeding HK$5 billion, and the top deals contributing the bulk of proceeds) drive most of the volume. For bankers, that means deal sourcing will increasingly favor larger, high-profile issuers.
Third, sectoral strength lies in industrials & materials, tech/IT/Telco, biotech/healthcare, and consumer/retail. Consumer goods and services led by deal count; industrials & materials by funds raised. The government’s push for domestic demand, innovation, and self-reliance amplifies these sectors’ attractiveness. Emerging technology sectors (AI, biotech, etc.) will be priority areas, supported by recent regulatory reforms.
Looking ahead to 2026: PwC and Deloitte anticipate HK$320-350 billion in IPO proceeds from ~150 successful listings, including more companies raising over HK$5 billion and continued influx of A-share companies. However, risks may chip away at growth: heightened Chinese regulation of AI and cybersecurity, global economic uncertainty (interest rates, trade policy), and investor sentiment shifts are all plausible headwinds.
For investment banks, this means opportunity will cluster with high-quality, large-scale deals and with issuers that have cross-border appeal. Advisory teams must also navigate tightening regulatory angles, build relationships across mainland China, and ensure readiness for emerging sectors. Capital markets teams should evaluate articulation of valuations under new listing regimes and be prepared for larger disclosure or compliance burdens. Open questions include the pace of regulation over AI/tech listings, how many of the current 300+ IPO applications convert, and whether global macro volatility might dampen investor risk appetite in 2026.
Supporting Notes
- Hong Kong raised HK$285.8 billion in IPO proceeds in 2025, a >2Ă— increase over 2024; 119 IPOs completed, up 68% from 2024.
- Of those 119 IPOs, 113 were Main Board listings, two GEM-to-Main Board transfers (without fundraising), one listing by introduction, two de-SPACs, one on GEM.
- Industry breakdown for Main Board IPOs: by deal count retail/consumer/services (28%), IT/Telco (26%), healthcare & pharma (25%); by capital raised industrials & materials (41%), followed by retail/consumer/services (27%), IT/Telco (18%).
- 55 companies raised at least HK$1 billion; more than ten are expected to raise over HK$5 billion in 2026; H-share listings surged from 30 in 2024 to 76 in 2025 (↑153%).
- PwC projects HK$320-350 billion in IPO proceeds from about 150 successful listings in 2026; emphasis on new economy (18C/18A biotech) and A-share companies tapping HKEX.
- Deloitte estimates eight IPOs in 2025 each raised >= HK$10 billion, contributing about half of total proceeds; 19 A+H listings contributed about half of proceeds; forecasts for 2026 are c.160 IPOs raising at least HK$300 billion.
- KPMG confirms over 300 active IPO applications as of Dec 2025; strong pipeline including 92 A+H applicants.
